| Literature DB >> 27701463 |
Kathrine Agergård Kaspersen1, Khoa Manh Dinh1, Lise Tornvig Erikstrup2, Kristoffer Sølvsten Burgdorf3, Ole Birger Pedersen4, Erik Sørensen3, Mikkel Steen Petersen1, Henrik Hjalgrim5, Klaus Rostgaard5, Kaspar Rene Nielsen6, Henrik Ullum3, Christian Erikstrup1.
Abstract
INTRODUCTION: The aim of this study was to examine whether low-grade inflammation (LGI) is associated with a subsequently increased risk of infection.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27701463 PMCID: PMC5049789 DOI: 10.1371/journal.pone.0164220
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the cohort.
| Women | Men | |
|---|---|---|
| 7,457 (47.3%) | 8,297 (52.7%) | |
| Age≤30 | 2,367 | 1,997 |
| 30>age≤40 | 1,736 | 2,152 |
| 40>age≤50 | 1,801 | 2,097 |
| 50>age≤60 | 1,152 | 1,426 |
| Age>60 | 401 | 625 |
| 37.8 (27.3; 47.9) | 40.0 (30.3; 49.9) | |
| 67.0 (61.0; 75.0) | 84.0 (76.0; 92.0) | |
| 169 (165; 173) | 182 (178; 187) | |
| 82.0 (76.0; 90.0) | 92 (86.0; 99.0) | |
| 23.5 (21.5; 26.2) | 25.1 (23.3; 27.4) | |
| 1,281 (17.0%) | 1,333 (16.1%) | |
| 2,204 (29.6%) | - | |
| BMI<18.5 (underweight) | 79 | 23 |
| 18.5≤BMI<25 (normal weight) | 4,822 | 4,038 |
| 25≤BMI<30 (overweight) | 1,842 | 3,386 |
| BMI≥30 (obese) | 714 | 850 |
| 0.66 (0.17; 1.87) | 0.41 (0.05; 1.09) | |
| CRP>3 | 1,068 | 494 |
| CRP>5 | 449 | 181 |
| 249 | 322 | |
| 197 | 207 | |
| 4,069 | 3,207 | |
| CRP≤3 | 0.5 (0.1; 1.2) | 0.4 (0.1; 0.9) |
| 3<CRP≤10 (LGI) | 0.7 (0.2; 1.9) | 0.4 (0.1; 1.1) |
| CRP>10 | 12.1 (11.0; 13.3) | 11.5 (10.5; 12.6) |
Numbers with percentages or medians with interquartile ranges.
a Charlson's index were calculated 15 years prior to inclusion.
The association between low-grade inflammation and infection.
| WOMEN | MEN | |||||||
|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | |||||||
| Site of infection | HR (95% CI) | HR (95% CI) | N | IR | HR (95% CI) | HR (95% CI) | ||
| 249 | 322 | |||||||
| CRP≤3 (reference) | 208 | 9.6 | 1 | 1 | 290 | 11.0 | 1 | 1 |
| 3<CRP≤10 (LGI) | 41 | 11.3 | 1.14 (0.81–1.59) | 1.06 (0.75–1.50) | 32 | 19.3 | 1.74 (1.21–2.51) | 1.60 (1.10–2.34) |
| 49 | 67 | |||||||
| CRP≤3 (reference) | 42 | 1.9 | 1 | 1 | 58 | 2.2 | 1 | 1 |
| 3<CRP≤10 (LGI) | 7 | 1.9 | 0.96 (0.43–2.14) | 0.80 (0.35–1.82) | 9 | 5.3 | 2.66 (1.31–5.39) | 2.19 (1.06–4.54) |
| 35 | 90 | |||||||
| CRP≤3 (reference) | 31 | 1.4 | 1 | 1 | 78 | 2.9 | 1 | 1 |
| 3<CRP≤10 (LGI) | 4 | 1.1 | 0.71 (0.25–2.05) | 0.87 (0.31–2.49) | 12 | 7.1 | 2.52 (1.36–4.65) | 2.07 (1.09–3.90) |
| 82 | 81 | |||||||
| CRP≤3 (reference) | 70 | 3.2 | 1 | 1 | 72 | 2.7 | 1 | 1 |
| 3<CRP≤10 (LGI) | 12 | 3.3 | 0.97 (0.52–1.79) | 0.98 (0.52–1.83) | 9 | 5.3 | 1.90 (0.94–3.81) | 1.80 (0.88–3.68) |
| 50 | 57 | |||||||
| CRP≤3 (reference) | 40 | 1.3 | 1 | 1 | 51 | 1.4 | 1 | 1 |
| 3<CRP≤10 (LGI) | 10 | 1.5 | 1.53 (0.76–3.07) | 1.45 (0.70–2.98) | 6 | 1.6 | 1.92 (0.82–4.50) | 1.81 (0.76–4.33) |
| 42 | ||||||||
| CRP≤3 (reference) | 31 | 1.4 | 1 | 1 | ||||
| 3<CRP≤10 (LGI) | 11 | 3.0 | 1.89 (0.94–3.77) | 1.66 (0.81–3.40) | ||||
Multivariable cox proportional hazards analysis was performed with LGI as predictor with age as the underlying timescale.
LGI is defined as a c-reactive protein (CRP) level between 3 and 10 mg/L.
a N: number of cases.
b IR: incidence rate per 1000 person-years.
c Model 1: multivariable cox proportional hazards analysis was performed with low-grade inflammation (LGI) as predictor.
d Model 2: multivariable-adjusted model based on model 1 with additional adjustments for obesity, current smoking status, and comorbidity.
The association between low-grade inflammation and prescriptions of antimicrobials.
| WOMEN | MEN | |||||||
|---|---|---|---|---|---|---|---|---|
| Site of infection | Model 1 | Model 2 | Model 1 | Model 2 | ||||
| Type of prescription | N | IR | HR (95% CI) | HR (95% CI) | N | IR | HR (95% CI) | HR (95% CI) |
| 4,069 | 3,207 | |||||||
| CRP≤3 (reference) | 3,455 | 332.0 | 1 | 1 | 2,986 | 200.1 | 1 | 1 |
| 3<CRP≤10 (LGI) | 614 | 370.1 | 1.08 (0.99–1.18) | 1.05 (0.96–1.15) | 221 | 248.2 | 1.22 (1.07–1.40) | 1.17 (1.02–1.35) |
| 2,097 | 1,951 | |||||||
| CRP≤3 (reference) | 1,770 | 134.0 | 1 | 1 | 1,806 | 108.0 | 1 | 1 |
| 3<CRP≤10 (LGI) | 327 | 151.0 | 1.13 (1.00–1.27) | 1.06 (0.93–1.19) | 145 | 141.9 | 1.29 (1.09–1.52) | 1.22 (1.03–1.45) |
| 677 | 559 | |||||||
| CRP≤3 (reference) | 550 | 36.8 | 1 | 1 | 516 | 27.9 | 1 | 1 |
| 3<CRP≤10 (LGI) | 127 | 51.8 | 1.46 (1.20–1.77) | 1.31 (1.07–1.60) | 43 | 37.2 | 1.28 (0.93–1.74) | 1.25 (0.91–1.72) |
| 367 | 432 | |||||||
| CRP≤3 (reference) | 321 | 20.9 | 1 | 1 | 394 | 21.0 | 1 | 1 |
| 3<CRP≤10 (LGI) | 46 | 17.9 | 0.88 (0.64–1.20) | 0.81 (0.59–1.12) | 38 | 32.4 | 1.54 (1.10–2.16) | 1.29 (0.92–1.82) |
| 1,156 | 119 | |||||||
| CRP≤3 (reference) | 980 | 68.3 | 1 | 1 | 111 | 5.8 | 1 | 1 |
| 3<CRP≤10 (LGI) | 176 | 73.5 | 1.00 (0.85–1.17) | 1.02 (0.87–1.21) | 8 | 6.6 | 0.97 (0.47–1.99) | 1.02 (0.49–2.13) |
| 467 | 305 | |||||||
| CRP≤3 (reference) | 377 | 24.8 | 1 | 1 | 277 | 14.7 | 1 | 1 |
| 3<CRP≤10 (LGI) | 90 | 35.7 | 1.35 (1.07–1.71) | 1.34 (1.05–1.70) | 28 | 23.7 | 1.61 (1.09–2.38) | 1.72 (1.15–2.55) |
| 325 | 286 | |||||||
| CRP≤3 (reference) | 272 | 17.7 | 1 | 1 | 261 | 13.8 | 1 | 1 |
| 3<CRP≤10 (LGI) | 53 | 20.6 | 1.26 (0.94–1.70) | 1.19 (0.88–1.62) | 25 | 21.0 | 1.37 (0.91–2.07) | 1.17 (0.77–1.78) |
Multivariable cox proportional hazards analysis was performed with LGI as predictor with age as the underlying timescale.
LGI is defined as a c-reactive protein (CRP) level between 3 and 10 mg/L.
a N: number of cases.
b IR: incidence rate per 1000 person-years.
c Model 1: multivariable cox proportional hazards analysis was performed with low-grade inflammation (LGI) as predictor.
d Model 2: multivariable-adjusted model based on model 1 with additional adjustments for obesity, current smoking status, and comorbidity.